Colorectal Cancer Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast The global colorectal cancer therapeutics market size is expected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing cases of colon and rectal cancer.
Colorectal cancer (CRC) is the third most common type of cancer, after lung and breast cancer. Colorectal cancer also called as bowel cancer and colon cancer. It is a type of cancer which affects the colon and the rectum by uncontrolled and abnormal division of cells leading to the formation of a malignant tumor. In-vitro colorectal cancer screening tests are done to check symptoms and presence of colorectal cancer. In this test prevalence of colorectal cancer in patients is confirmed by understanding the progression and nature of this cancer. Exact causes of CRC are unspecified. Though, various environmental and genetic factors are responsible for rising the risk of disease development. Based on the American Cancer Society, in the U.S., around 1 out of 21 men and 1 in 23 women are projected to progress colorectal cancer in their lifetime. However, prevalence of colorectal cancer is reducing over the last few years because of advanced diagnostics and screening along with improved treatment. Emergence of front-line therapies and increasing initiatives by government are projected to aid the market. Increasing adoption of unhealthy habits, inactive lifestyle habits, and rising consumption of alcohol and tobacco smoking are responsible for inflammatory intestinal conditions which leads rising cases of colorectal cancer. Acceptance of advanced therapies is rising. Some of the advanced therapies includes Avastin (bevacizumab), Erbitux (cetuximab), and Stivarga (regorafenib), which helps the expansion of the market. Patent of major products such as Avastin, Vectibix, and Zaltrap are projected to lose over the forecast period. Hence, expiration of patent leads to increase in penetration of biosimilars. Amgen and Allergan’s Mvasi were first biosimilar to Avastin approved in U.S. and Europe. Due to which biosimilars mark the entry into oncology field. Other biosimilars such as bevacizumab and cetuximab are anticipated to impact branded sales after launch.